课题基金 / 基金详情

New Modalities of Chimeric Antigen Receptor (CAR) Therapies in Pediatric Rhabdomyosarcoma

New Modalities of Chimeric Antigen Receptor (CAR) Therapies in Pediatric Rhabdomyosarcoma
嵌合抗原受体 (CAR) 治疗小儿横纹肌肉瘤的新方法
批准号：
456857
负责人：
Haddad Elie
金额：
$33.51万
依托单位：
Centre hospitalier universitaire Sainte-Justine (Montral, Qubec)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
已结题
起止时间：
2021-09-01 至 2023-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=456857&lang=en
关键词：
Cancer Immunotherapy Car-Nk Cells Car-T Cells Chimeric Antigen Receptor Engineered Stem Cells Patient-Derived Xenograft Rhabdomyosarcoma Solid Tumors Synthetic Specific Promoters Translational Aspect Of Gene Therapy

项目摘要

项目成果

Haddad Elie的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Rhabdomyosarcoma (RMS) is the most common soft tissue cancer in childhood. Although progress in treatments have led to a remission rate of approximatively 60% of all pediatric cases, the prognosis of patients with high-risk RMS is still very poor. Therefo
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The interplay between Inborn Error of Immunity and blood disorders: unravelling immune defects behind common haematological diseases
Empowering innovative hematopoietic stem cells (HSC)-based cancer immunotherapy through the creation of synthetic specific promoters
Platform of synthetic specific promoters for immunotherapies and regenerative medicine
Alternatives to current Chimeric-Antigen Receptor (CAR)-T cell therapy in acute lymphoblastic leukemia
海外基金